Shc Inhibitor Program
Lung Fibrosis
About Buto
Buto Corp is a private, preclinical biotech founded in 2020, targeting the Shc protein pathway to develop anti-fibrotic and anti-inflammatory therapies. The company's platform is based on inhibiting the Shc protein, which is implicated in driving fibrosis and neurodegeneration. Its initial pipeline is focused on lung and liver fibrosis, with exploratory work in Alzheimer's disease. Buto operates as a pre-revenue, research-focused entity, positioning itself in large, underserved markets with significant unmet medical need.
View full company profileAbout Buto
Buto Corp is a private, preclinical biotech founded in 2020, targeting the Shc protein pathway to develop anti-fibrotic and anti-inflammatory therapies. The company's platform is based on inhibiting the Shc protein, which is implicated in driving fibrosis and neurodegeneration. Its initial pipeline is focused on lung and liver fibrosis, with exploratory work in Alzheimer's disease. Buto operates as a pre-revenue, research-focused entity, positioning itself in large, underserved markets with significant unmet medical need.
View full company profileAbout Buto
Buto Corp is a private, preclinical biotech founded in 2020, targeting the Shc protein pathway to develop anti-fibrotic and anti-inflammatory therapies. The company's platform is based on inhibiting the Shc protein, which is implicated in driving fibrosis and neurodegeneration. Its initial pipeline is focused on lung and liver fibrosis, with exploratory work in Alzheimer's disease. Buto operates as a pre-revenue, research-focused entity, positioning itself in large, underserved markets with significant unmet medical need.
View full company profile